S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.04%) $0.927
USD/NOK
(0.26%) $10.87
USD/GBP
(0.05%) $0.793
USD/RUB
(-0.29%) $92.31

Realtime updates for Xencor Inc [XNCR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 3.05%
SELL
33.33%
return -1.74%
Last Updated28 Mar 2024 @ 16:00

-1.29% $ 22.13

SELL 63211 min ago

@ $19.46

Issued: 14 Feb 2024 @ 09:30


Return: 13.72%


Previous signal: Feb 13 - 09:31


Previous signal: Buy


Return: -3.52 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases...

Stats
Today's Volume 499 971
Average Volume 739 113
Market Cap 1.35B
EPS $0 ( 2024-02-27 )
Next earnings date ( $-0.0900 ) 2024-05-05
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -10.64
ATR14 $0.0180 (0.08%)
Insider Trading
Date Person Action Amount type
2024-03-11 Kuch John J Sell 849 Common Stock
2024-03-11 Eckert Celia Sell 850 Common Stock
2024-03-11 Desjarlais John R Sell 1 280 Common Stock
2024-03-11 Dahiyat Bassil I Sell 2 741 Common Stock
2024-03-06 Gustafson Kurt A Buy 15 000 Common Stock
INSIDER POWER
62.14
Last 97 transactions
Buy: 2 670 677 | Sell: 459 713

Volume Correlation

Long: -0.02 (neutral)
Short: -0.87 (strong negative)
Signal:(47.193) Neutral

Xencor Inc Correlation

10 Most Positive Correlations
THRX0.898
WDC0.891
PALT0.886
TREE0.883
OZKAP0.882
OTRK0.881
XPEL0.873
HLMN0.871
MBIO0.869
TCBIO0.862
10 Most Negative Correlations
GLDI-0.814
CFV-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xencor Inc Correlation - Currency/Commodity

The country flag 0.63
( weak )
The country flag -0.01
( neutral )
The country flag 0.00
( neutral )
The country flag 0.69
( moderate )
The country flag -0.14
( neutral )
The country flag -0.28
( neutral )

Xencor Inc Financials

Annual 2023
Revenue: $168.34M
Gross Profit: $156.84M (93.17 %)
EPS: $-2.08
Q4 2023
Revenue: $44.69M
Gross Profit: $41.46M (92.78 %)
EPS: $-0.310
Q3 2023
Revenue: $59.16M
Gross Profit: $56.02M (94.69 %)
EPS: $-0.400
Q2 2023
Revenue: $45.52M
Gross Profit: $42.64M (93.66 %)
EPS: $-0.370

Financial Reports:

No articles found.

Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators